Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
Total Valuation
Arrowhead Pharmaceuticals has a market cap or net worth of $1.62B. The enterprise value is $2.67B.
Market Cap$1.62B
Enterprise Value$2.67B
Share Statistics
Arrowhead Pharmaceuticals has 137.32M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding137.32M
Owned by Insiders4.15%
Owned by Instutions22.41%
Financial Efficiency
Arrowhead Pharmaceuticals’s return on equity (ROE) is -3.23 and return on invested capital (ROIC) is -57.37%.
Return on Equity (ROE)-323.27%
Return on Assets (ROA)-52.60%
Return on Invested Capital (ROIC)-57.37%
Return on Capital Employed (ROCE)-57.98%
Revenue Per Employee$4,105.09
Profits Per Employee-$1,050,433.498
Employee Count609
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arrowhead Pharmaceuticals is -3.87. Arrowhead Pharmaceuticals’s PEG ratio is -0.02.
PE Ratio-3.87
PS Ratio653.40
PB Ratio12.51
Price to Fair Value12.51
Price to FCF-3.84
Price to Operating Cash Flow-5.01
PEG Ratio-0.02
Income Statement
In the last 12 months, Arrowhead Pharmaceuticals had revenue of $2.50M and earned -$639.71M in profits. Earnings per share was -$3.79.
Revenue$2.50M
Gross Profit-$6.81M
Operating Income-$625.95M
Pretax Income-$646.75M
Net Income-$639.71M
EBITDA-580.69M
Earnings Per Share (EPS)-3.79
Cash Flow
In the last 12 months, operating cash flow was -$491.28M and capital expenditures -$80.33M, giving a free cash flow of -$571.61M billion.
Operating Cash Flow-$491.28M
Free Cash Flow-$571.61M
Free Cash Flow per Share-$4.16
Dividends & Yields
Arrowhead Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-26.05%
Earnings Yield-25.84%
Stock Price Statistics
Beta2.10
52-Week Price Change-50.90%
50-Day Moving Average16.40
200-Day Moving Average20.76
Relative Strength Index (RSI)38.87
Average Volume (3m)1.95M
Important Dates
Arrowhead Pharmaceuticals upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateFeb 10, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Arrowhead Pharmaceuticals as a current ratio of 6.74, with Debt / Equity ratio of 2.75
Current Ratio6.74
Quick Ratio6.74
Debt to Market Cap0.17
Net Debt to EBITDA-0.73
Interest Coverage Ratio-18.58
Taxes
In the past 12 months, Arrowhead Pharmaceuticals has paid -$1.05M in taxes.
Income Tax-$1.05M
Effective Tax Rate0.45%
Enterprise Valuation
Arrowhead Pharmaceuticals EV to EBITDA ratio is -4.86, with an EV/FCF ratio of -4.51.
EV to Sales768.26
EV to EBITDA-4.86
EV to Free Cash Flow-4.51
EV to Operating Cash Flow-5.89
Balance Sheet
Arrowhead Pharmaceuticals has $552.93M in cash and marketable securities with $115.86M in debt, giving a net cash position of -$437.08M billion.
Cash & Marketable Securities$552.93M
Total Debt$115.86M
Net Cash-$437.08M
Net Cash Per Share-$3.18
Tangible Book Value Per Share$1.52
Margins
Gross margin is 100.00%, with operating margin of -16927.06%, and net profit margin of -16882.37%.
Gross Margin100.00%
Operating Margin-16927.06%
Pretax Margin-17247.54%
Net Profit Margin-16882.37%
EBITDA Margin-15812.81%
EBIT Margin-16336.47%
Analyst Forecast
The average price target for Arrowhead Pharmaceuticals is $40.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$40.60
Price Target Upside244.36%
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast-98.62%
EPS Growth Forecast-86.21%